Plasma levels of 7-hydroxylated dehydroepiandrosterone (DHEA) metabolites and selected amino-thiols as discriminatory tools of Alzheimer's disease and vascular dementia
Language English Country Germany Media print
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
15202788
DOI
10.1515/cclm.2004.088
Knihovny.cz E-resources
- MeSH
- 17-alpha-Hydroxypregnenolone blood MeSH
- Alzheimer Disease blood diagnosis MeSH
- Biomarkers blood MeSH
- Cysteine analogs & derivatives blood MeSH
- Dehydroepiandrosterone analogs & derivatives blood MeSH
- Dehydroepiandrosterone Sulfate blood MeSH
- Dipeptides blood MeSH
- Glutathione blood MeSH
- Homocysteine blood MeSH
- Middle Aged MeSH
- Humans MeSH
- Logistic Models MeSH
- Statistics, Nonparametric MeSH
- Predictive Value of Tests MeSH
- Pregnenolone blood MeSH
- Radioimmunoassay MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Sensitivity and Specificity MeSH
- Sex Factors MeSH
- Sulfhydryl Compounds blood MeSH
- Dementia, Vascular blood diagnosis MeSH
- Chromatography, High Pressure Liquid MeSH
- Check Tag
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- 17-alpha-Hydroxypregnenolone MeSH
- 7-hydroxydehydroepiandrosterone MeSH Browser
- Biomarkers MeSH
- Cysteine MeSH
- cysteinylglycine MeSH Browser
- Dehydroepiandrosterone MeSH
- Dehydroepiandrosterone Sulfate MeSH
- Dipeptides MeSH
- Glutathione MeSH
- Homocysteine MeSH
- Pregnenolone MeSH
- pregnenolone sulfate MeSH Browser
- Sulfhydryl Compounds MeSH
OBJECTIVE: The early differential diagnosis of Alzheimer's disease (AD) remains still problematic. We developed a laboratory test enabling us to distinguish patients with AD from those with vascular dementia (VD) and healthy subjects. METHODS: The AD group consisted of 22 women and 18 men. The VD group consisted of 16 women and 8 men. Age-matched controls consisted of 12 women and 9 men. Plasma pregnenolone sulfate (PregS), dehydroepiandrosterone (DHEA) and its sulfate (DHEAS) were determined by radioimmunoassay. 17-Hydroxypregnenolone (17Preg) and 7-hydroxylated metabolites of DHEA (7alphaDHEA, 7betaDHEA) were determined by radioimmunoassay after separation by high performance liquid chromatography (HPLC). Homocysteine (Hcy), cysteine (Cys), cysteinylglycine (Cysgly) and glutathione (GSH) were measured by HPLC. RESULTS: The ANOVA results of significant between-group differences were as follows: The PregS and the 17-Preg and DHEAS levels were independent from the diagnosis. The 7alphaDHEA levels significantly depended on the sex (p < 0.05) and diagnosis (p < 0.01). Amino-thiols were influenced by the diagnosis (p < 0.01, p = 0.0541, p < 0.01 and p = 0.0536 for Cys, Hcy, Cysgly and GSH, respectively). Using a stepwise backward regression analysis, the following parameters were obtained: X = 11.5 + 4.03 x sex +1.09 x Hcy + 0.190 x PregS - 4.76 x DHEAS + 3.00 x DHEA - 34.3 x 77alphaDHEA - 0.885 x Cysgly from which P-value as a discriminator was calculated according to the formula: P = 1/(1 + e(-x)). Then, for P > 0.5, a subject was considered as AD-positive (with 89% correct prediction). DISCUSSION: The opportunity of early differential diagnosis of AD should help physicians to use suitable treatment for retardation of pathological processes.
References provided by Crossref.org
